Featured Publications
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse events
2017
Online Sales of Unscheduled Pharmaceutical Agents
Gupta S, Wallace R, Sloshower J. Online Sales of Unscheduled Pharmaceutical Agents. Journal Of Addiction Medicine 2017, 11: 411-412. PMID: 28742625, DOI: 10.1097/adm.0000000000000342.Peer-Reviewed Original ResearchConceptsSignificant withdrawal syndromeUse of tianeptineMu-opioid receptorsMajor depressive disorderPharmaceutical agentsWithdrawal syndromeTricyclic antidepressantsDepressive disorderGeneral populationHealth storesDrug AdministrationMedical providersHigh dosesTianeptineDietary supplementsUnmonitored useCognition enhancersAntidepressantsDosesResearch chemicalsUnited StatesDiscontinuationPatientsSignificant harmSertraline